Loading news...
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Citigroup Inc. cut its position in shares of AnaptysBio, Inc. (NASDAQ: ANAB) by 93.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 70,534 shares of the biotechnology company's stock after selling 975,954 shares during the quarter. Citigroup Inc. owned 0.25% of
AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to a loss of $0.72 per share a year ago.
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonist GSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rate Expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys at GSK's peak sales guidance of >$2.7 billion as early as 2029 Year-end 2025 cash and investments of ~$311 million SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec. 31, 2025. “We are approaching a defining inflection point for Anaptys, as we plan to spin-off in Q2 2026 our wholly owned biopharma portfolio into a public company, to be called First Tracks Biotherapeutics, to unlock and amplify value for investors across two distinct sets of assets,” said Daniel Faga, president and chief executive officer of Anaptys.
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026. GPP is a rare, chronic, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms such as fever and fatigue.
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Summary FMB WEALTH MANAGEMENT initiated a new position in AnaptysBio Inc(ANAB), purchasing 5,592 shares valued at approximately $271,100 as of its late
Campbell and CO Investment Adviser LLC bought a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,281 shares of the biotechnology company's stock, valued at approximately $560,000. Campbell and CO Investment
AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J.
The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45,738 to 42,088 shares, as reported.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Paul Lizzul sold 3,650 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the transaction, the insider owned 42,088 shares of the company's stock,
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 14,281 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $638,503.51. Following the transaction, the chief executive officer directly owned 479,344 shares of the
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 9,639 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.56, for a total transaction of $439,152.84. Following the completion of the transaction, the insider owned 9,157 shares in the company, valued
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 9,202 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares in the company, valued at
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sales of the cancer drug Jemperli.
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exclusive License Agreement (“Collaboration Agreement”), which entitles Anaptys to receive royalties upon sales of Jemperli.
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 10,000 shares of the company's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $46.00, for a total value of $460,000.00. Following the transaction, the insider directly owned 9,088 shares in the company, valued at $418,048.